Real-world procedural and 30-day outcome using the Portico transcatheter aortic valve prosthesis: A large single center cohort

Denegri, Andrea; Nietlispach, Fabiàn; Kottwitz, Jan; Suetsch, Gabor; Haager, Philipp K.; Rodríguez, Hector P.; Taramasso, Maurizio; Obeid, Slayman

doi:10.1016/j.ijcard.2017.10.101

Cited by 13 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Portico is a self-expanding repositionable and retrievable transcatheter aortic valve prosthesis, with a low incidence of PVL reported in the literature (1,2).…”

Section: Clinical Resultsmentioning

confidence: 99%

Surgical aortic valve replacement due to infective endocarditis after transcatheter aortic valve implantation with the self-expanding Portico valve prosthesis

Sugimura

Katahira

Lopez

et al. 2019

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

“…Portico is a self-expanding repositionable and retrievable transcatheter aortic valve prosthesis, with a low incidence of PVL reported in the literature (1,2).…”

Section: Clinical Resultsmentioning

confidence: 99%

Surgical aortic valve replacement due to infective endocarditis after transcatheter aortic valve implantation with the self-expanding Portico valve prosthesis

Sugimura

Katahira

Lopez

et al. 2019

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

“…Sameer Hirji 1 , MD, MPH; Gregory Leya 2 , MD, MBA; Marc Pelletier 1 *, MD, MSc We found the recent study by Maisano et al very thought-provoking, given the focus on the commercial experience using the Portico™ bioprosthetic valve (Abbott, Santa Clara, CA, USA) in the multicentre PORTICO-1 study 1 . We applaud the authors for conducting this important study which further adds to a growing body of evidence demonstrating the overall safety (low mortality) and acceptable clinical and haemodynamic outcomes (low transvalvular gradients and low rate of moderate-high paravalvular leak) of the Portico valve [2][3][4] .…”

Section: Are We Compromising On Value Versus Performance: Time To Consider the Portico Valve As A Third Major Market Player?mentioning

confidence: 95%

“…In particular, the Portico valve, an acceptable and viable option in many countries, is gaining appreciable interest and has shown comparable haemodynamic performance to the newer-generation valves [2][3][4] . Unfortunately, the lack of head-to-head comparison has hindered its growth due to concerns over safety and performance.…”

Section: Are We Compromising On Value Versus Performance: Time To Consider the Portico Valve As A Third Major Market Player?mentioning

confidence: 99%

Are we compromising on value versus performance: time to consider the Portico valve as a third major market player?

Hirji¹,

Leya²,

Pelletier³

2019

EuroIntervention

View full text Add to dashboard Cite

“…The following supporting information can be downloaded at: . Table S1: Comparison of designs and major results of known Portico THV studies [ 20 , 21 , 22 , 24 , 25 , 37 , 45 ].…”

mentioning

confidence: 99%

Real-Life Performance and Clinical Outcomes of Portico Transcatheter Aortic Valve with FlexNav Delivery System: One-Year Data from a Single-Center Experience

Yildirim,

Genc,

Pacaci

et al. 2023

JCM

View full text Add to dashboard Cite

Significant progress has been made in both valves and delivery systems (DSs) for transcatheter aortic valve replacement (TAVR) procedures. We aimed to present one-year real-life data regarding TAVR procedures using Portico transcatheter heart valves (THVs) with new-generation, low-profile FlexNav DSs. This retrospective, single-center study enrolled 169 consecutive patients (mean age: 75.8 years, 68% females) with severe aortic stenosis undergoing TAVR with Portico THVs and FlexNav DSs between 2020 and 2021. We evaluated safety and efficacy outcomes, following the VARC-3 consensus, periprocedurally and at 30 days and 1 year. Procedural success was observed in 95.9% of cases, and no procedural mortality occurred. At 30 days, the rates of all-cause mortality, cardiovascular mortality, and neurological events were 4.7%, 3.6%, and 3.0%, respectively. Additionally, major vascular complications, acute kidney injury, and bleeding were recorded at rates of 11.2%, 14.8%, and 7.7%, respectively. The 1-year data showed all-cause mortality, cardiovascular mortality, and neurological event rates of 10.7%, 8.3%, and 7.7%, respectively. The moderate paravalvular leak and permanent pacemaker rates at 1 year were 2.6% and 12.2%, respectively. This real-life data provided evidence of positive outcomes and high technical success with Portico THVs and FlexNav DSs. Furthermore, we found low rates of mortality and neurological events, with satisfactory hemodynamic and functional results.

show abstract

Real-world procedural and 30-day outcome using the Portico transcatheter aortic valve prosthesis: A large single center cohort

Cited by 13 publications

References 16 publications

Surgical aortic valve replacement due to infective endocarditis after transcatheter aortic valve implantation with the self-expanding Portico valve prosthesis

Surgical aortic valve replacement due to infective endocarditis after transcatheter aortic valve implantation with the self-expanding Portico valve prosthesis

Are we compromising on value versus performance: time to consider the Portico valve as a third major market player?

Real-Life Performance and Clinical Outcomes of Portico Transcatheter Aortic Valve with FlexNav Delivery System: One-Year Data from a Single-Center Experience

Contact Info

Product

Resources

About